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Abstract Using fluorescence optical and electron spin reso-
nance spectroscopy, we have investigated the production of
superoxide by bovine endothelial nitric oxide synthase (NOS). In
contrast to neuronal NOS, the heme moiety is identified as the
exclusive source of superoxide production by endothelial NOS.
Thus, calmodulin-mediated enzyme regulation affects production
of nitric oxide and superoxide simultaneously and inseparably.
The balance between the nitric oxide/superoxide reaction path-
ways may be shifted by addition of exogenous heme-specific
agents, such as tetrahydrobiopterin. Our results have direct
relevance for the pathophysiology of atherosclerosis.
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1. Introduction
The dualistic nature of nitric oxide synthases (NOS), pro-
ducing both nitric oxide (NO) and superoxide, has stimulated
research with regard to the exact (patho)physiological role of
NOS [1]. In the literature, neuronal NOS (nNOS) has clearly
been identi¢ed as a source of superoxide production, where
both the £avin and heme domains proved capable of oxygen
radical production [2]. For endothelial NOS (eNOS) the sit-
uation is less clear. Of note, eNOS di¡ers from nNOS in
several ways. Endothelial NOS is unique among the NOS
isoforms in being dually acylated. This property is required
for eNOS binding and targeting to caveolae in the endothelial
plasma membranes [3]. Activity of eNOS is regulated by a
balanced interaction of eNOS with either the activating cal-
modulin or the inhibiting caveolin-1 [4].
In view of the role of eNOS in atherogenesis, the question
whether superoxide can be generated by the £avin domain of
eNOS remains of crucial importance. Since the calmodulin-
binding site and the heme-containing oxygenase domain are
the only places accessible for therapeutic manipulation of
eNOS, exact location of the superoxide-producing site has
direct therapeutic consequences. In the present study we
have addressed the following questions. First, does eNOS
produce oxygen radicals? Second, what is the localization of
oxygen radical production within the eNOS enzyme, consist-
ing of a £avin reductase domain and a heme-containing oxy-
genase domain? Third, is it possible to modulate (pathologi-
cal) shifts in NO/superoxide production by eNOS?
As a model for human eNOS we have used the baculovirus-
expressed bovine eNOS.
2. Materials and methods
2.1. Materials
Recombinant bovine eNOS, expressed in a baculovirus/Sf9 system,
was obtained from Cayman Chemical Co. (Ann Arbor, MI, USA).
Using gel electrophoresis, more than 90 weight % of the enzyme was
in a dimeric state. The recombinant enzyme has been characterized as
a functional analogue of native eNOS [5,6]. The spin trap 5-diethoxy-
phosphoryl-5-methyl-1-pyrroline-N-oxide (DEPMPO) was purchased
from Calbiochem-Novabiochem GmbH (Bad Soden, Germany). L-
[2,3,4,5-3H]Arginine HCl (57 Ci/mmol) was purchased from Amer-
sham (Vienna, Austria). (6R)-5,6,7,8-Tetrahydro-L-biopterin (BH4)
was from Alexis (Nottingham, UK). Diphenyl iodonium (DPI) was
obtained from Aldrich (Munich, Germany). All other chemicals were
from Sigma.
2.2. Electron spin resonance
Production of superoxide was detected indirectly by spin trapping
(ESR) with the recently introduced spin trap DEPMPO. ESR experi-
ments were carried out on a modi¢ed Bruker ESP 300 X band spec-
trometer equipped with a Bruker rectangular cavity operating in the
TE102 mode. For EPR experiments a typical reaction mixture con-
sisted of 20 Wl DEPMPO (¢nal concentration 50 mM), 5 Wl eNOS (8
mg/ml) and various concentrations of cofactors, added with phosphate
bu¡er (pH 7.4) to a ¢nal volume of 200 Wl. The cofactors which were
exogenously added to a standard reaction mixture were calcium chlor-
ide, calmodulin, NADPH and L-arginine. After thorough mixing sam-
ples (35 Wl) were drawn by a syringe into a quartz capillary. This
capillary was mounted on a te£on holder and placed within the cavity.
Measurements were performed under aerobic conditions at room tem-
perature with microwave power of 10 mW, microwave frequency of
9.44 GHz. The spectrum of DEPMPO was recorded at a magnetic ¢eld
of 3370 Gauss with a sweep width of 200 Gauss. The magnetic ¢eld
was modulated with a frequency of 100 kHz and amplitude 1 Gauss.
The detector gain was 1.25U106, the time constant 41 ms and ADC
conversion time 82 ms. Accumulating four scans enhanced the signal
to noise ratio (S/N ratio). Quantitation of the free radical signal was
performed by comparison of the S/N ratio. The measurements were
performed in duplicate, 20 min after incubation of the enzyme.
2.3. Determination of NO production
NO production was determined as described previously [7]. In
short, the formation of radioactive L-[2,3,4,5-3H]citrulline from L-
[2,3,4,5-3H]arginine was measured with 45 Wg eNOS, incubated with
0.5 mM NADPH, 1 mM CaCl2, 300 U/ml calmodulin, followed by
separation on Dowex AG 50W-X4 and detection of [3H]citrulline. All
measurements were performed in triplicate. The reaction was per-
formed in either the presence or the absence of tetrahydrobiopterin
15 WM, L-arginine 10 WM or the calcium chelator EDTA 10 mM.
2.4. Optical spectroscopy
Steady state UV-vis £uorescence emission and excitation spectra
were measured under aerobic conditions at room temperature on a
SPF 500 spectro£uorimeter (SLM-Aminco instruments) with 1 mm
quartz cuvette. The £uorescence spectra were recorded as a function
of emission wavelength, with the excitation wavelength ¢xed at
Vexc = 443 nm [8]. The excitation spectra were recorded as a function
of excitation wavelength, with the observation wavelength ¢xed at
Vobs = 525 nm. The monochromator bandwidths were set at 2 nm.
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3. Results
3.1. Oxygen radical adduct formation
In principle, a variety of di¡erent oxygen radicals may give
rise to the formation of these adducts. We have identi¢ed the
radical involved in eNOS-derived adduct formation as super-
oxide by addition of speci¢c radical inhibitors. Thus, super-
oxide dismutase (SOD, 300 U/ml) completely abolished ad-
duct formation, whereas catalase (10 U/ml) and the iron
chelator DTPA (10 mM) did not reduce the DEPMPO-adduct
signal (Fig. 1). In favorable cases the shape of the ESR spec-
trum also allows direct identi¢cation of the radical, which
gives rise to the adduct formation. For DEPMPO, the spectra
of the superoxide and hydroxyl radical adducts have been
reported as characteristically di¡erent in the literature [9]. Di-
rect visual comparison shows that our eNOS-induced ESR
spectra have low intensity and a shape di¡erent from the
DEPMPO-OOH adduct reported (Fig. 2) [9]. In order to
test whether the adduct line shape depends on the rate of
superoxide production, we have performed a series of DEPM-
PO trapping experiments on solutions with varying concen-
trations of the superoxide-generating system hypoxanthine-
xanthine oxidase. At low hypoxanthine-xanthine oxidase con-
centrations (respectively 0.5 mM; 1 U/ml) we observed adduct
spectra identical to those observed in our eNOS samples (Fig.
2). At higher hypoxanthine-xanthine oxidase concentrations
(respectively 1 mM; 80 mU/ml) the shape of the adduct spec-
tra changed to the form reported in the literature [9] as that of
the DEPMPO-OOH adduct. For all trapping experiments on
hypoxanthine-xanthine oxidase the adduct formation was in-
hibitable by SOD, whereas catalase and DTPA had no e¡ect
on adduct formation.
3.2. Localization of superoxide production within eNOS
enzyme
Calcium chelation with EDTA (10 mM), which disrupts
calmodulin-mediated electron transfer between the £avin re-
ductase domain and the heme oxygenase domain, inhibits
both superoxide and NO production (Figs. 1 and 4). We
have used luminescence spectroscopy to observe the redox
state of the £avin groups. Upon excitation at 443 nm the
£avins have a characteristic £uorescence emission at 525 nm
in the oxidized state, whereas the reduced form is not lumi-
nescent. eNOS without cofactors produced a clear £uores-
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Fig. 1. Superoxide adduct formation by eNOS: e¡ect of inhibitors.
Fig. 2. Electron spin resonance spectra of spin trap adducts. A:
eNOS. B: Xanthine oxidase (1 mU/ml) and hypoxanthine (0.5 mM).
C: Xanthine oxidase (80 mU/ml) and hypoxanthine (1 mM). The
broad background is caused by impurities in the quartz glassware
and unrelated to the trapping experiments. Fig. 3. Superoxide adduct formation by eNOS: e¡ect of cofactors.
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cence signal at a ¢xed detection wavelength of 525 nm. The
corresponding excitation spectrum had a line shape character-
istic of £avins. Upon addition of the cofactors calmodulin,
calcium chloride and NADPH, the £uorescence signal re-
mained una¡ected, signifying very rapid restoration of the
£avins to their oxidized states, presumably by rapid electron
transfer towards the heme group (Fig. 5). After addition of
the calcium chelator EDTA (10 mM), the £avin luminescence
was strongly suppressed (Fig. 5). Suppletion of excess calcium
chloride restored the luminescence intensity towards the orig-
inal value, i.e. eNOS without cofactors (Fig. 5), accounting
for a 10% dilution of the signal by adding the calcium chloride
solution.
3.3. External modulation of the superoxide-NO balance
In the presence of NAPDH, L-arginine, calcium and cal-
modulin a clear radical adduct was observed with ESR
(Fig. 3). The adduct formation was completely abolished by
SOD (300 U/ml) and the £avin reductase inhibitor DP
(100 WM) (Fig. 2). Addition of the L-arginine analogue, L-
NAME (0.1 M), did not alter the ESR signal intensity
(Fig. 3). In contrast, upon exogenous addition of the cofactor
BH4 (15 WM), the ESR intensity decreased (Fig. 3). As as-
sessed by the production of L-[2,3,4,5-3H]citrulline, NO pro-
duction was totally inhibited by DPI (Fig. 4). Addition of L-
NAME (0.1 M) practically annihilated the NO production.
Addition of exogenous BH4 (15 WM) caused a more than
twofold increase in NO production (Fig. 4).
4. Discussion
4.1. Main conclusions
In the bovine eNOS model we clearly detect the formation
of superoxide radicals with ESR after incubation with
NADPH, calcium and calmodulin. Blockade of eNOS-medi-
ated superoxide production, combined with disappearance of
the speci¢c £uorescence of the £avin groups in eNOS upon
calcium chelation, shows that the heme moiety of eNOS is the
exclusive source of superoxide production by eNOS. Addition
of exogenous BH4 decreases eNOS-mediated superoxide pro-
duction.
4.2. Origin of superoxide production within the eNOS enzyme
Arguments have been put forward favoring superoxide pro-
duction by the £avin domain, by the heme domain or by both
domains of eNOS [2,10,11]. In our eNOS model, removal of
calcium by the calcium chelator EDTA completely prevented
superoxide production. Since calmodulin serves as an electron
shuttle between the reductase and oxygenase domains [12],
this suggests the necessity of electron transfer from the £avin
moiety to the heme moiety for superoxide production to oc-
cur. Since calmodulin binding has also been suggested to af-
fect the a⁄nity of the £avin reductase domain for NAPDH
[2], one can consider two di¡erent mechanisms, which may
account for the inhibitory e¡ect of calcium depletion. First,
calcium depletion detaches calmodulin from eNOS, somehow
disabling the capacity of the reductase domain to receive the
electrons from NADPH, thereby inactivating the eNOS en-
zyme as a whole. Alternatively, the reductase domain remains
functional and accepts electrons from the NADPH. However,
the £avin domain remains in its reduced state, since it cannot
pass the electrons on to the heme group in the absence of
calmodulin.
The redox state of the £avin groups within the eNOS en-
zyme can be evaluated due to their speci¢c absorbance and
£uorescence properties [8]. Since eNOS concentrations were
insu⁄cient for direct detection of the optical absorption by
eNOS, we used £uorescence spectroscopy, which allowed de-
tection of £uorescence emission around V= 525 nm in concen-
trated eNOS solutions (8 mg/ml) in the absence of cofactors.
This £uorescence was attributed to £avins in the oxidized
state, since both the absorption peaks (443 and 475 nm, as
detected in the excitation spectrum) and the £uorescence emis-
sion spectra were characteristic for oxidized £avoproteins [8].
Since the £avins do not £uoresce in the reduced state, the
£uorescence properties of eNOS provide a convenient and
sensitive method to study the £avin redox state under exper-
imental conditions. Upon addition of cofactors, the £uores-
cence behavior is unchanged. This shows that the £avins re-
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Fig. 5. Fluorescence emission spectrum of £avin groups in the re-
ductase domain of eNOS. A: eNOS with cofactors. B: Addition of
the calcium chelator EDTA (10 mM). C: Addition of excess calci-
um chloride (500 mM) on top of EDTA.
Fig. 4. NO production by eNOS. NO production expressed as pmol
[3H]citrulline/min/mg enzyme.
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main predominantly in the oxidized state. Since NADPH is
being consumed, this indicates a rapid electron transfer from
the reduced £avins to the heme group, thereby restoring the
£avins to their oxidized state. Upon calcium chelation by
EDTA, £avin £uorescence is strongly suppressed, demonstrat-
ing that the £avin reductase domain still extracts electrons
from the cofactor NADPH. Despite the reduced state of the
£avin reductase domain, no radical adduct formation could be
demonstrated upon EDTA addition. Addition of excess cal-
cium chloride restores electron £ow to the heme moiety. Ac-
cordingly, the £avin £uorescence reappears. Simultaneously,
NOS-derived radicals are again detected with ESR. These
observations validate the second option and we therefore con-
clude that the £avin domain remains functional in the absence
of calmodulin. The concomitant lack of oxygen radical for-
mation shows that the heme domain is exclusively responsible
for eNOS-mediated superoxide production. This property
constitutes a clear di¡erence with nNOS, where both the
heme domain and the £avin domain contribute to oxygen
radical production [2]. This ¢nding in eNOS has two impor-
tant implications. First, localized production of superoxide by
the heme domain means that for eNOS superoxide production
can be externally switched via calmodulin- and/or heme-spe-
ci¢c agents. Second, a high priority should be given to the
question whether and how the balance between the superoxide
and nitric oxide production by eNOS may be in£uenced by
exposure to external agents.
4.3. Shift in NO/superoxide balance by external agents
The substrate of eNOS, L-arginine, as well as an essential
cofactor for NOS, tetrahydrobiopterin (BH4), have both been
implicated to have an ameliorative e¡ect during NOS dysfunc-
tion [13,14]. To evaluate whether these agents are able to
cause a shift in the NO/superoxide balance of eNOS, we
have tested the e¡ect of both BH4 suppletion and L-arginine
depletion. Addition of exogenous BH4 to eNOS resulted in a
decrease in superoxide adduct formation, whereas NO pro-
duction, assessed as conversion of [3H]arginine to
[3H]citrulline, increased more than twofold. These data are
in accordance with earlier ¢ndings, where depletion of BH4
has been shown to cause a shift from NO to superoxide and
its superoxide dismutase product hydrogen peroxide by puri-
¢ed neuronal NOS [13,15]. Recently, we have extended these
¢ndings to a clinical study, where BH4 co-infusion reinforced
NO activity in hypercholesterolemic patients in vivo [14].
With regard to the mechanism of BH4-induced changes, we
note that the BH4-induced dimerization [2,14] of eNOS alone
is not su⁄cient to explain the enhanced NO production, since
the enzyme was used in the dimeric state, as assessed by gel
electrophoresis [7].
Addition of excess L-NAME completely abolished NO pro-
duction, whereas superoxide production by eNOS remained
una¡ected. In the presence of L-NAME, the production of
superoxide could still be downregulated by subsequent addi-
tion of exogenous BH4. In this respect, eNOS (again) di¡ers
from neuronal and inducible NOS, where previous studies
[10,15] have reported the abolition of superoxide formation
by L-NAME. This shows that the heme moiety of eNOS
remains capable of redox activity even in the presence of L-
NAME. Further research will have to elucidate (a) to what
extent the ¢ndings are a¡ected by di¡erences between isolated
enzyme systems and the enzyme in viable cells and (b) the
e¡ect of additional risk factors, e.g. LDL cholesterol, on the
kinetics of eNOS [16,17].
4.4. Implications for (patho)physiology
From the present study the following interesting ¢ndings
may have implications for the relation between human vascu-
lar disease and eNOS. First, the simultaneous generation of
both NO and superoxide, even in the presence of BH4 and L-
arginine, proves that eNOS may serve as a peroxynitrite-pro-
ducing enzyme under physiological conditions. Our data cor-
roborate the data of Mayer et al. [18], who have argued that
neuronal NOS produces ONOO rather than NO. Second,
therapeutic interventions aimed at increasing NO production,
such as eNOS transfection [19] and eNOS stimulation, will
invariably also result in increased production of oxygen rad-
icals. The ultimate e¡ect depends on the local balance between
oxygen radical stress and NO production. Hence, strategies
for cardiovascular prevention should aim at restoration of
the redox dysbalance and alteration of the NO/superoxide
balance by eNOS, rather than focusing on increasing NO
production per se [20].
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